Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.

Front Med (Lausanne) · 2021 · PMC8440866 · PMID 34540860

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

did not reach statistical significancep = 0.065so close (0.05 < p ≤ 0.1)

However, the proportion of patients achieving EASI-50 in the 2 mg baricitinib group did not reach statistical significance at 16 weeks ( p = 0.065).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.